Search Results
Results 251 - 300 of 681
< 1 2 3 4 5 6 7 8 9 10 11 >
Abraham J S - - 1994
Two patients sustained the rare complication of skin infarction following administration of intravenous streptokinase for acute myocardial infarction. We report evidence that dissolution of thrombus from an unsuspected source and subsequent microembolization of the skin may be responsible for this complication. In patients known to have an aortic aneurysm or ...
Mohan G - - 1994
In an attempt to find the prognostic value of serum magnesium in various complications, serum magnesium was estimated spectrophotometrically, in patients of acute myocardial infarction. There was a statistically insignificant difference in serum magnesium levels of complicated group of patients (1.627 +/- 0.192 mg/100 mL) and those who had uneventful ...
Gemmill J D - - 1994
OBJECTIVE: To evaluate the influence of pretreatment streptokinase resistance titre and the concentration of IgG antibodies to streptokinase on the efficacy of thrombolytic drugs containing streptokinase in restoring coronary patency in acute myocardial infarction. DESIGN: Comparative observational study. SETTING: City general hospital. PATIENTS: One hundred and twenty four previously unexposed ...
Hansen P R - - 1994
The clinical benefit of streptokinase (SK) in the treatment of patients with acute myocardial infarction may be influenced by effects other than myocardial reperfusion per se. Polymorphonuclear leucocytes (PMNs) have been hypothesized to participate in the process of reperfusion injury in the postischemic myocardium. The purpose of the present study ...
- - 1994
Previous small clinical trials have suggested that treatment with nitric oxide donors in suspected myocardial infarction can reduce mortality by 30-35%. To confirm this finding in a large-scale trial, we compared molsidomine and its active metabolite linsidomine (a nitric oxide donor) with placebo in 4017 patients with acute myocardial infarction. ...
Weiss M - - 1994
When given at physiological doses, therapy with magnesium corrects the alterations in cellular function resulting from magnesium deficiency, whereas at higher dosages, which induce hypermagnesaemic levels, magnesium possesses pharmacological effects, such as the inhibition of the calcium influx: this may alter the electrophysiological properties of heart cells, decrease catecholamine secretion, ...
Kurita T - - 1994
Magnesium deficiency has been linked with cardiac arrhythmias and sudden cardiac death. Antiarrhythmic effects of intravenous magnesium in the patients who are not hypomagnesaemic were mainly demonstrated in the patients with acquired long QT syndrome. Parenteral administration should be considered in this type of ventricular tachycardia, because its use is ...
Lee K L - - 1994
The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, a recent randomized "megatrial" of thrombolytic therapies in acute myocardial infarction, showed a statistically significant decrease of 30-day mortality in patients treated with accelerated-dose tissue plasminogen activator (tPA) compared with streptokinase. The therapeutic and cost ...
van der Wall E E - - 1994
Nisoldipine is a calcium antagonist with potent coronary vasodilating effects in patients with chronic stable angina pectoris. In an initial study we showed that intravenous nisoldipine, given 24-72 hours after uncomplicated myocardial infarction, was a safe and feasible intervention that had beneficial effects on global and regional myocardial function. We ...
McCully J D - - 1994
Cytosolic calcium in the myocardium is rapidly accumulated during ischemia and has been correlated with the attenuation of functional recovery in the myocardium. The aged myocardium is more sensitive to ischemia and accumulates significantly more cytosolic calcium than either the newborn or the mature myocardium. Modification of the age-related propensity ...
Chakrabarty S - - 1994
Despite variable efficacy in achieving recanalization, different thrombolytic agents demonstrate similar abilities to reduce mortality following myocardial infarction. We investigated whether factors other than the ability to achieve coronary artery recanalization are important in mediating the beneficial effects associated with thrombolytic therapy during acute myocardial infarction using anaesthetized rabbits. Coronary ...
Woods K L - - 1994
The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) examined the effect of an intravenous regimen of magnesium sulphate in 2316 patients with suspected acute myocardial infarction. Treatment, according to a double-blind randomised protocol, was started with a loading injection, before any thrombolytic therapy, and continued with a maintenance infusion for ...
de Boer M J - - 1994
OBJECTIVES: The purpose of the present study was to compare intravenous streptokinase therapy with immediate coronary angioplasty without antecedent thrombolytic therapy with regard to left ventricular function and hospital mortality and reinfarction. BACKGROUND: Despite the widespread use of intravenous thrombolytic therapy and immediate percutaneous transluminal coronary angioplasty, these two strategies ...
MBewu A D - - 1994
BACKGROUND: Lp(a) lipoprotein has structural homology with plasminogen and has been shown to inhibit plasminogen activation in vitro. OBJECTIVE: To determine whether the serum concentration of Lp(a) lipoprotein present when streptokinase was given in acute myocardial infarction influenced the outcome as judged by electrocardiographic methods. PATIENTS AND DESIGN: Serum Lp(a) ...
Lidón R M - - 1994
BACKGROUND: The success of streptokinase in acute myocardial infarction is hampered by the high failure rate to achieve early reperfusion. This study evaluates the possible benefit of Hirulog (Biogen, Cambridge, Mass), a direct thrombin inhibitor, as adjunct therapy to streptokinase to enhance early patency and prevent rethrombosis. Heparin has been ...
Roffe C - - 1994
OBJECTIVE: To examine the effect of doubling serum magnesium concentration on the incidence of arrhythmias in patients with suspected acute myocardial infarction. DESIGN: Randomised double blind clinical trial. SETTING: Coronary care unit of a teaching hospital. PATIENTS: Clinical data were collected on 2316 randomised patients with suspected acute myocardial infarction. ...
Battershill P E - - 1994
Streptokinase has been administered to many thousands of elderly patients with acute myocardial infarction. Results of large, randomised trials provide convincing evidence that intravenous streptokinase confers a distinct survival benefit in this population subgroup following myocardial infarction. The placebo-controlled ISIS-2 study demonstrated a 5-week absolute mortality reduction of 38 per ...
Shibley M H - - 1994
Urokinase is an endogenously produced human proteolytic enzyme used to treat many thrombotic disorders. A 54-year-old man with recurrent myocardial infarction experienced fever during intracoronary urokinase infusion into a saphenous vein graft; the fever resolved after discontinuation of the infusion. After excluding all other possible etiologies of fever, urokinase was ...
Simko F - - 1994
Intravenous administration of magnesium has proved to have beneficial effect in acute myocardial infarction. Magnesium seems to act at different levels of the cardiovascular system. Of the greatest importance is the direct influence of Mg2+ on the cardiomyocyte which includes: reduction of cytoplasmatic calcium overload, protection of mitochondria against calcium ...
Reganon E - - 1993
In 15 patients with acute myocardial infarction who received 1,500,000 U of streptokinase, the gradual appearance of newly synthesized fibrinogen and the fibrinopeptide release during the first 35 h after SK treatment were evaluated. At 5 h the fibrinogen circulating in plasma was observed as the high molecular weight fraction ...
Millane T - - 1993
Magnesium deficit in man is very difficult to detect and even more difficult to study. However, a chance observation led to the investigation of cardiac transplant recipients as an in vivo model of drug-induced magnesium depletion. Clinical circumstances were such that the question of the correlation of serum and tissue ...
Chua T P - - 1993
OBJECTIVE: To determine if serum cholesterol concentration should be measured before or after streptokinase therapy within the first 24 h of myocardial infarction. DESIGN: Prospective study of patients receiving streptokinase therapy for acute myocardial infarction (AMI). SETTING: Coronary care unit of a district general hospital. SUBJECTS: Thirty-one patients (26 men ...
Van de Werf F - - 1993
The mortality results for the four arms of the GUSTO trial are presented. The 30 day mortality results were as follows: streptokinase (SK) and subcutaneous heparin (n = 9796), 7.2%, SK and intravenous heparin (n = 10,377) 7.4%, accelerated tissue plasminogen activator (t-PA) and intravenous heparin (n = 10,344) 6.3%, ...
- - 1993
BACKGROUND: Although it is known that thrombolytic therapy improves survival after acute myocardial infarction, it has been debated whether the speed with which coronary-artery patency is restored after the initiation of therapy further affects outcome. METHODS: To study this question, we randomly assigned 2431 patients to one of four treatment ...
Bashir Y - - 1993
Magnesium deficiency frequently develops in patients with congestive heart failure and may increase susceptibility to lethal arrhythmias and sudden death via multiple pathophysiologic mechanisms. The effects of peroral magnesium supplementation were investigated in a randomized, double-blind, crossover trial involving 21 patients with stable congestive heart failure secondary to coronary artery ...
Houweling P L - - 1993
Sixty ASA Grade II-III patients, without clinical symptoms of ventricular dysfunction and scheduled for elective bifemoral grafting for abdominal aneurysms, were allocated randomly to three equal groups to receive 150 micrograms sufentanil intravenously, epidurally or intrathecally. All patients received midazolam, vecuronium and nitrous oxide. Except for right ventricular stroke work ...
- - 1993
A double-blind controlled trial was performed to evaluate the dose-effect relationship of APSAC on coronary reperfusion in patients with acute myocardial infarction. A total of 103 patients were recruited in 14 centres and randomly allocated to receive 3.75, 7.5, 15.0 or 30.0 U of anisoylated plasminogen streptokinase activator complex (APSAC), ...
Hix C D - - 1993
Magnesium plays an important role in the functioning of the cardiovascular system. A decrease in magnesium has been linked with tachydysrhythmias, increased mortality in patients with congestive heart failure, and increased mortality after an acute myocardial infarction. The research shows that the use of magnesium supplements in these situations may ...
- - 1993
BACKGROUND: The relative efficacy of streptokinase and tissue plasminogen activator and the roles of intravenous as compared with subcutaneous heparin as adjunctive therapy in acute myocardial infarction are unresolved questions. The current trial was designed to compare new, aggressive thrombolytic strategies with standard thrombolytic regimens in the treatment of acute ...
Teo K K - - 1993
A number of small, randomised clinical trials and one large trial of intravenous magnesium have been conducted on patients with acute myocardial infarction (AMI). Most of these trials indicate that treatment with magnesium has a beneficial effect on short term mortality, although in most of the small trials the results ...
Mass H - - 1993
With the advent of pharmacological, mechanical and surgical revascularization as firstline therapies in acute coronary artery disease syndromes, the search for adjunctive pharmacotherapy against reocclusion and reperfusion injury has intensified. In addition, safe pharmacotherapeutic intervention conferring survival advantage is required for those at high risk ineligible for recanalization or beta ...
Hishamuddin H M - - 1993
Thrombolytic therapy is a well-established therapy in acute myocardial infarction (AMI), reducing mortality and infarct size. This study is a retrospective analysis of survival and complications after the use of streptokinase at Hospital Universiti Sains Malaysia. Streptokinase was first used here in March 1990. Between then and February 1992, 126 ...
Patel S - - 1993
OBJECTIVE: To follow the change in streptokinase neutralisation titres in a group of patients after treatment with streptokinase for acute myocardial infarction. DESIGN: Venous blood samples suitable for analysis were obtained up to 866 days after treatment with 1.5 million units of streptokinase in 189 patients. The ability of the ...
Shaheen B E - - 1993
The mechanisms of magnesium action and the possible benefits of its use in treating acute myocardial infarction are reviewed. Magnesium is an essential cofactor in more than 300 enzymatic reactions, including those responsible for the production, storage, and use of energy. It influences impulse generation and action potential propagation of ...
Tsutsui M - - 1993
It has been hypothesized that intracellular magnesium deficiency is a pathogenetic factor in acute myocardial infarction. This study examined the time course of changes in the erythrocyte magnesium concentration and the correlation between the erythrocyte magnesium concentration and the severity of acute myocardial infarction in 49 consecutive patients with transmural ...
Collen D - - 1993
BACKGROUND: Staphylokinase (STA), a protein with known profibrinolytic properties, is produced by transduced Staphylococcus aureus strains. In experimental animal models, recombinant staphylokinase (STAR) is less immunogenic and more active toward platelet-rich arterial blood clots than streptokinase. METHODS AND RESULTS: In the present study, 10 mg STAR given intravenously over 30 ...
Norris R M - - 1993
OBJECTIVE: To validate a simple noninvasive method with serial creatine kinase measurements for diagnosis of early patency of the infarct related artery after thrombolytic treatment with streptokinase. To investigate the relation between early patency of the infarct related artery and prognosis. DESIGN: Patients under 76 years of age and seen ...
Chouhan L - - 1993
Despite early treatment with thrombolytic agents for acute myocardial infarction, a significant portion of patients fail to achieve a patent infarct artery. To study the various factors related to achieving patency in the infarct vessel, 201 patients who received streptokinase within six hours of symptoms were studied. All patients underwent ...
Obel N - - 1993
The neutrophil granulocyte seems to be intimately involved in the destructive processes leading to myocardial damage observed in ischaemic/reperfusion injuries. The process may cause stress to the peripheral circulating neutrophils leading to exhaustion and decreased function. We conducted a study in which the function of peripheral neutrophil granulocytes was measured ...
Gottlieb S S - - 1993
Intravenous magnesium is an effective treatment for ventricular tachycardia of some etiologies, and in patients with congestive heart failure low serum magnesium concentrations are associated with frequent arrhythmias and high mortality. This suggests that magnesium administration may decrease the frequency of ventricular arrhythmias in patients with heart failure. We therefore ...
Rude R K - - 1993
Magnesium is a prominent intracellular cation required for the function of hundreds of enzyme systems. Magnesium depletion is observed frequently in hospitalized patients and is usually secondary to renal or intestinal magnesium loss. Clinically, magnesium deficiency may present with neuromuscular hyperexcitability, hypocalcemia, hypokalemia, and cardiac arrhythmias. Magnesium therapy appears to ...
- - 1993
This paper presents the results of a multicentric study on the use of intravenous streptokinase as thrombolytic therapy in acute myocardial infarction. Its aim was to assess the benefits and complications of this therapy in Indian conditions. The study comprised 510 cases from 31 hospitals, employing a common protocol. 1.5 ...
MacMillan A R - - 1993
A 52-year-old man ingested 60 ml of 2 percent topical minoxidil solution resulting in severe hypotension and tachycardia. He was resuscitated with intravenously administered crystalloid solution and treated with intravenously administered dopamine, resulting in a partial hemodynamic improvement. Further treatment with intravenously administered phenylephrine infusion resulted in resolution of hypotension. ...
Thögersen A M - - 1993
A total of 109 consecutive patients were included in a double blind, randomized trial of the effect of intravenous magnesium sulfate in acute myocardial infarction. Of these 63% received intravenous fibrinolytic therapy. Twenty four-hour Holter monitoring of heart rhythm was performed during the initial hospital stay. A significant reduction in ...
Flapan A D - - 1993
OBJECTIVES: The purpose of the study was to compare cardiac parasympathetic activity during the early and convalescent phases of acute anterior and inferior myocardial infarction. BACKGROUND: Previous studies have shown that cardiac parasympathetic activity may vary with the site of infarction and that recovery may occur after infarction. METHODS: Cardiac ...
Zijlstra F - - 1993
BACKGROUND: Despite the widespread use of intravenous thrombolytic therapy and of immediate percutaneous transluminal coronary angioplasty for the treatment of acute myocardial infarction, randomized comparisons of the two approaches to reperfusion are lacking. We report the results of a prospective, randomized trial comparing immediate coronary angioplasty (without previous thrombolytic therapy) ...
Baxter-Jones C S - - 1993
The results of an overview of early (90-240 min) and late (24 hours or more) patency and of stroke rates for each of the three commercially available thrombolytic agents, streptokinase, alteplase, and anistreplase are presented. Studies included in this analysis are all those published between 1985 and March 1992 and ...
Nicolau J C - - 1993
Our objective was to investigate variables which, although occurring during the acute period, could influence the medium (1st year) and long-term (6th year) survival of infarcted patients. Of a total of 332 patients treated consecutively and prospectively according to the same protocol which included intravenous streptokinase, 305 survived the hospital ...
Norris R M - - 1993
BACKGROUND: We investigated whether the proportion of creatine kinase (CK) MM3 to total MM isoform, measured in a single blood specimen taken at 3 hours after starting intravenous administration of streptokinase to patients with developing myocardial infarction, would give reliable information on patency or occlusion of the infarct-related coronary artery. ...
Krause T - - 1993
In a subgroup of 45 patients with acute myocardial infarction (AMI) from the German multicenter trial of anisoylated plasminogen streptokinase activator complex (APSAC) (n = 20) versus heparin (n = 25), simultaneous thallium (TI)-201 technetium (Tc)-99m pyrophosphate (PYP) tomography was initiated to elucidate a possible benefit of APSAC over heparin. ...
< 1 2 3 4 5 6 7 8 9 10 11 >